Sweetgreen reported a wider-than-expected net loss and missed revenue estimates for Q2 2026, leading to a significant stock decline and an analyst downgrade. The company also revised its full-year outlook downward due to reduced demand following a cyclosporiasis outbreak, indicating ongoing challenges despite management's long-term confidence.
Sweetgreen's Q2 2026 financial results were significantly below Wall Street expectations, with a wider net loss and revenue miss. This underperformance, coupled with a 6.2% decline in same-store sales and a lowered full-year outlook, directly led to a sharp stock price decline and an analyst downgrade. The revised guidance, attributed to reduced demand post-cyclosporiasis outbreak, highlights a significant short-term headwind for the company. While management expresses long-term confidence, traders are reacting to the immediate negative financial performance and outlook, indicating continued pressure on SG shares until operational improvements and demand recovery are evident.